Selective estrogen receptor modulator (SERM)-associated nonalcoholic fatty liver disease (NAFLD) might be related to treatment efficacy in patients with breast cancer because of circulating estrogen antagonism. Here, ESR1 is linked to metabolic dysfunction-associated steatotic liver disease.